PatientsVille.com Logo


Plasmalyte Medical Research Studies

Up-to-date List of Plasmalyte Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Plasmalyte Medical Research Studies

Rank Status Study
1 Recruiting Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach
Conditions: Hypotension;   Kidney Injury
Interventions: Drug: Plasmalyte 3ml/kg/hr group;   Drug: Plasmalyte 6ml/kg/hr group
Outcome Measures: Renal injury;   Pulmonary Edema;   Length of Surgical Intensive Unit stay/hospital Stay;   Removal of Chest Tubes;   Morbidity;   Death;   Arterial Blood Gases
2 Recruiting Effects of IV Chloride Content on Outcomes
Conditions: SIRS;   Balanced Fluids;   Plasmalyte
Outcome Measures: Mortality;   Length of Stay;   Acute renal failure;   Infections;   dysrhythmias;   Electrolyte disorders
3 Not yet recruiting Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)
Condition: Respiratory Distress Syndrome, Adult
Interventions: Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells;   Biological: Plasma-Lyte A
Outcome Measures: Incidence of pre-specified infusion associated events occurring within 6 hours of study infusion;   Any cardiac arrest or death within 24 hours of study infusion;   Any unexpected severe adverse events in two groups;   Respiratory efficacy endpoints which include lung injury score, PaO2/FiO2 ratio and oxygenation index at day 3.;   Systemic efficacy endpoints which include SOFA score, ventilator-free days, organ failure free days, mortality, et al.;   Biological efficacy endpoints which includes serial levels of plasma and urine biomarkers.
4 Unknown  Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral Stroke
Condition: Stroke
Interventions: Biological: Ex vivo cultured adult allogenic MSCs;   Other: Plasmalyte-A
Outcome Measures: The type of AE(s), number of AE(s) and proportion of patients with AE(s).;   Improvement of neurological recovery as assessed by NIH Stroke Scale (NIHSS).;   Improvement of the Functional recovery - assessed by Barthel's Index for activities of daily living.;   Improvement of Global outcome as assessed by the Modified Rankin Scale;   MRI Parameters - Change in infarct size T2 - weighted images and blood flow in infarct area as evaluated by Diffusion Weighted Index
5 Recruiting The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial
Condition: Anterior Wall Myocardial Infarction
Interventions: Biological: Plasma-Lyte A and 25% Autologous Plasma;   Biological: Autologous EPCs;   Biological: Autologous EPCs Transfected with human eNOS
Outcome Measures: Assessment of Global LVEF;   Assessment of: Cardiac wall motion and volumes;   Time To Clinical Worsening (TTCW);   Safety Measurements
6 Not yet recruiting Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%
Conditions: Coronary Artery Disease;   Aortic Valve Disease;   Mitral Valve Disease
Interventions: Other: prime crystalloid;   Other: Human Albumin;   Other: Voluven
Outcome Measures: Post-operative bleeding and transfusion requirements;   renal function, creatinine levels
7 Not yet recruiting Does the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?
Condition: Patients Undergoing Cardiothoracic Surgery
Intervention: Other: Low-chloride perioperative intravenous fluid strategy
Outcome Measures: Peak delta serum creatinine and Class 2 or greater AKI, defined by KDIGO criteria, while in ICU. (Co-primary outcomes);   Individual stages of AKI, RRT, renal function at discharge, 30 days and 90 days postoperatively, hospital mortality, length of stay, time to extubation and transfusion requirements
8 Recruiting Randomized Phase II Multicentre Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With Glioblastoma Multiforme Measured Compared to Avastin/Irinotecan
Condition: Glioblastoma Multiforme
Interventions: Biological: ALECSAT;   Drug: Bevacizumab/Irinotecan
Outcome Measures: Progression-free survival (PFS);   Overall survival (OS);   Time to progression (TTP);   Quality of Life by European Organization for Research and Treatment of Cancer (EORTC) questionnaire;   Overall Response Rate (ORR)

These studies may lead to new treatments and are adding insight into Plasmalyte etiology and treatment.

A major focus of Plasmalyte research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Plasmalyte